不同剂量丙种球蛋白治疗ABO溶血病疗效比较

目的比较不同剂量静脉注射用丙种球蛋白(IVIG)治疗新生儿ABO血型不合溶血病的疗效。方法将出生后2 d内确诊的新生儿ABO血型不合溶血病患儿随机分为单剂组(70例)和多剂组(66例),单剂组静脉滴注IVIG 1 g/(kg.d),1 d;多剂组剂量500 mg/(kg.d),共3 d。生后第42天随访血红蛋白及生长发育等情况。结果单剂组需要双面光疗时间较多剂组短(P<0.01),两组患儿第42天血红蛋白水平、贫血发生率差异无显著性,两组患儿均不需换血治疗,均未发生胆红素脑病。结论单次大剂量IVIG(1 g/kg)治疗新生儿ABO血型不合溶血病是一种高效、经济、安全的治疗方法。

A study on different doses of intravenous immunoglobulins for treating ABO hemolytic disease of the newborn

Objective To observe the effect of different doses of intravenous immunoglobulins(IVIG) for treating ABO hemolytic disease of the newborn(ABO-HDN).Methods One hundred and thirty-six neonates in 2 days old with ABO-HDN were divided into two groups,trial group and control group.Seventy cases in the trial group were treated with IVIG(1g/kg,iv,1d),and 66 cases in the control group were treated with IVIG(500 mg/kg·d,iv,3d).Hemoglobin level,growth and development were followed up at their 42 days old.Results The duration of phototherapy in the trial group was significantly shorter than that in the control group(P<0.01).At the 42 days follow up,there was no statistic difference in the incidence of anemia and hemoglobin level between two groups.All patients did not require exchange transfusion,and bilirubin encephalopathy was not occurred.Conclusions High-dose IVIG treatment is an efficient,economical and safe treatment for ABO-HDN.It will be helpful in clinical management of ABO-HDN.